论文部分内容阅读
贺福立适甲型肝炎 (甲肝 )灭活疫苗 (HavrixTM)历经 1 0年的免疫推广和市场检验 ,证明该疫苗免疫原性强 ,一般人群接种后可获得持久保护 ,而慢性肝病或免疫缺陷者接种后同样也可产生保护性抗体。接种后监测资料已证实了其良好的安全性 ,而且证实其加强免疫的接种时机对免疫效果并无明显影响 ,为去甲肝高流行区的旅行者预防接种提供了方便。由于贺福立适甲肝灭活疫苗可在短期内使机体产生抗体 ,产生抗体所需的时间在甲肝潜伏期以内 ,因此可用于控制甲肝的爆发和暴露后的预防接种。由于中流行区甲肝病毒感染情况发生了明显转变 ,甲肝的免疫策略已发展为儿童、青少年普遍接种再加上高风险人群预防接种的策略
He Fu Li HAVrixTM vaccine (HAVrixTM) after 10 years of immunization and market tests proved that the vaccine is highly immunogenic, the general population can be sustained after vaccination, and chronic liver disease or immunodeficiency were vaccinated After the same can also produce protective antibodies. Monitoring data after vaccination has confirmed its good safety, but also confirmed that the timing of vaccination to enhance immunity has no significant effect on the immune effect, providing convenience for travelers in areas with high prevalence of hepatitis A vaccination. Since Hefu Li’s hepatitis A inactivated vaccine can produce antibodies to the body within a short period of time, the time required for antibody production is within the latent period of hepatitis A, so it can be used to control the outbreak of hepatitis A and the vaccination after exposure. As a result of the significant shift in hepatitis A virus infection in endemic areas, the immunization strategy for hepatitis A has developed into children, universal vaccination among adolescents and the strategy of vaccination in high-risk populations